Alamar Biosciences, Inc.
ALMR - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.12B
Close$
$2.56
91.1% downside
Current Fair Value
91.1% downsideOvervalued by 91.1% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $2.12 Billion |
|---|---|
| Enterprise Value | $2.04 Billion |
| Earnings per Share | $-0.45 |
| Beta | -6.18 |
| Outstanding Shares | 58,665,055 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -57.74 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | 5.79 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.16 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-0.31
Consensus analyst estimateRevenue Estimate
$25.86 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$-0.20
Consensus analyst estimateRevenue Estimate
$30.22 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.13%▼ 35.41% |
|---|---|
| Total Invested | $2.61M▼ 99.61% |
| Investors Holding | 6▼ 82.00% |
About Alamar Biosciences, Inc.
222 employees
CEO: Yuling Luo
Alamar Biosciences operates as a commercial-stage proteomics firm, specializing in the highly sensitive, simultaneous identification of various proteins for both scientific research and prospective medical applications. Their integrated ...